Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042224 · ClinicalTrials.gov registry record · Phase 1
Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT00042224 is a Phase 1 study of Schizophrenia that has completed, run by Northwell Health. The registered enrollment target is 39 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00042224, a Phase 1 study of Schizophrenia, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate electroconvulsive therapy (ECT) in patients who have not responded adequately to clozapine.
Conditions Studied
Interventions
- DRUG Clozapine
- PROCEDURE Electroconvulsive Therapy (ECT)
Study Locations (1)
New York
- Zucker Hillside Hospital - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2000-12 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042224
The ClinicalTrials.gov registry entry for NCT00042224 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Clozapine is the first listed.
NCT00042224 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00042224 about?
NCT00042224 is a clinical study titled "Electroconvulsive Therapy in Clozapine Refractory Schizophrenia". This study will evaluate electroconvulsive therapy (ECT) in patients who have not responded adequately to clozapine.
What is the current status of trial NCT00042224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2000-12. Estimated completion is 2008-07.
What conditions does trial NCT00042224 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00042224?
The interventions under investigation include: Clozapine (DRUG), Electroconvulsive Therapy (ECT) (PROCEDURE).
Who is sponsoring clinical trial NCT00042224?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00042224 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.